Discounted Cash Flow Calculation for DB:7R8 using 2 Stage Free Cash Flow to Equity Model
The calculations below outline how an intrinsic value for
is arrived at by discounting future cash flows to their present value using the 2 stage method.
We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.
DB:7R8 DCF 1st Stage: Next 10 year cash flow forecast
The current share price of
is above its future cash flow value.
Often investors are willing to pay a
for a company that has a high dividend or the potential for future growth.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.
The amount the stock market is willing to pay for
is considered below, and whether this is a fair price.
Price based on past earnings
Replimune Group's earnings available for a low price, and how does
this compare to other companies in the same industry?
Replimune Group is not considered high growth as it is expected to be loss making for the next 1-3 years.
Unable to determine if Replimune Group is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can
be gauged below. We look back 3 years and see if they were any good at
predicting what actually occurred. We also show the highest and lowest estimates
looking forward to see if there is a wide range.
Replimune Group's performance over the past 5 years by checking for:
Has earnings increased in past 5 years? (1 check)
Has the earnings growth in the last year exceeded that of the
industry? (1 check)
Is the recent earnings growth over the last year higher than the average annual growth over the
past 5 years? (1 check)
Is the Return on Equity (ROE) higher than 20%? (1 check)
Is the Return on Assets (ROA) above industry average? (1 check)
Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent
earnings report. Some checks require at least 3 or 5 years worth of data.
has a total score of
0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
Management is one of the most important areas of a company. We look at
unreasonable CEO compensation, how long the team and board of directors have
been around for and insider trading.
TENURE AS CEO
Dr. Robert Coffin, Ph.D. also known as Rob, co-founded Replimune Ltd and serves as its Chief Executive Officer. Dr. Coffin serves as President, Chief Executive Officer and Director at Replimune Group, Inc since 2015. He Co-Founded BioVex Group, Inc. and served as its Chief Scientific Officer since 1999. Dr. Coffin was the inventor of all BioVex products including OncoVEXGM-CSF (talimogene laherparepvec; T-VEC) and oversaw all research and clinical development including bringing T-VEC through to two pivotal phase 3 studies in melanoma and head & neck cancer under SPA before sale of BioVex to Amgen in 2011 where he became Vice President of Global Development until 2013. Dr. Coffin was a founding scientist and Lecturer in Virology and Gene Therapy at University College London and Honorary Senior Lecturer at The Institute of Child Health. He is an expert in the application of virus-based technology to the development of therapeutic products and vaccines, has authored more than 50 scientific papers and is a named inventor on all of the patents filed in BioVex name. He served as a Director of Replimune Ltd until July 10, 2017. He served as Director of BioVex Group, Inc. Dr. Coffin received his PhD in 1991 from Imperial College, London, following which he moved to University College London where he ultimately led the research group.
Insufficient data for Rob to compare compensation growth.
Rob's remuneration is higher than average for companies of similar size in Germany.
Management Team Tenure
Average tenure and age of the
management team in years:
The tenure for the Replimune Group management team is about average.
Chief Operating Officer
Chief Business Officer
Chief Accounting Officer
Chief Medical Officer
Board of Directors Tenure
Average tenure and age of the
board of directors in years:
The tenure for the Replimune Group board of directors is about average.
Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company uses its proprietary Immulytic platform to design and develop product candidates that are intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1 that is in Phase I/II clinical trials for a range of solid tumors. The company is also developing RP2, which is in Preclinical trials to express an anti-CTLA-4 antibody-like protein in order to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Preclinical trials to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.